Table 2.

Results of KRAS testing by five CLIA-certified laboratories

Sample ID	Clinical Result*	Sequencing Lab 1	Sequencing Lab 2	Sequencing Lab 3	Primer Extension Lab 4	Real-time PCR Lab 5
1	WT**	WT	WT	WT	WT	WT
2	WT	WT	WT	WT	WT	WT
3	WT	WT	WT	WT	WT	WT
4	WT	WT	WT	WT	WT	WT
5	WT	WT	WT	WT	WT	WT
6	WT	WT	G12D	G12D	WT	WT
7	G12V	G12V	G12V	G12V	G12V	G12V
8	G12D	G12D	G12D	G12D	G12D	G12D
9	G12V	G12V	G12V	G12V	G12V	G12V
10	G12S	G12S	G12S	G12S	G12S	G12S
11	G12V	G12V	G12V	G12V	G12V	G12V
12	G12C	G12C	G12C	G12C	G12C	G12C
13	G12V	G12V	G12V	G12V	G12V	G12V
14	G12D	WT†	G12D	G12D	G12D	G12D
15	G13D	G13D	G13D	G13D	G13D	G13D
16	G13D	G13D	G13D	G13D	G13D	G13D
17	G13D	G13D	G13D	G13D	G13D	G13D
18	G13D	G13D	G13D	G13D	G13D	G13D
19	G13D	G13D	G13D	G13D	G13D	G13D
20	G13D	G13D	G13D	G13D	G13D	G13D

*Samples were selected for testing based on these prior clinical results.

^**WT: wildtype; G12D: p.Gly12Asp; G12V: p.Gly12Val; G12S: p.Gly12Ser;

G13D: p.Gly13Asp.

^†This laboratory did see some evidence that the sample had a mutation, but was below the confidence threshold. This specimen showed tumor enrichment of approximately 40%, which is at the lower level of detection for this laboratory.